In the December 2014 issue of this publication, the author of an article entitled Drug-Induced Hepatotoxicity of Select Herbal Therapies discusses the safety of Herbalife products and other substances. The author presents a significant amount of information related to Herbalife which is outdated and some of which has more recently been challenged in the scientific community due to inaccurate and/or inconclusive assessment measures previously conducted. As such, it is important that the readership have the opportunity to draw their conclusions based on a more balanced and accurate view of the information provided in this article.
First and foremost, it should be acknowledged that Herbalife has rebutted the various publications which are cited, none of which are referenced by this author. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] The authors reference an article by Stickel et al, which implicates Herbalife products in 2 cases of Bacillus subtilis contamination. 11 Of note, Herbalife has previously rebutted these allegations in other publications to highlight critical deficiencies in the methodology used for the isolation of this bacteria from the product samples. 4 Furthermore, the evaluation of B subtilis' potential pathogenic role in these individuals appears highly unlikely, given the ubiquitous nature of B subtilis in the food supply and its long-standing history of safe use in various foods and ingredients.
As is frequently the case in publications involving historic Herbalife cases, these authors have omitted any reference to publications by third-party expert reviewers who question the validity of past methodology used to evaluate these cases. [12] [13] [14] In fact, it has been suggested by Teschke et al that many cases of hepatotoxicity which have been alleged to be causally associated with Herbalife products are showing weaker causality outcomes than previously determined. The primary reasons for inaccurate assessments of these cases include misapplication of the Council for International Organizations of Medical Sciences (CIOMS) assessment criteria, which is the globally accepted method for the evaluation of liver-related adverse event cases and/or the fact that potential alternative etiologies were not properly ruled out. Furthermore, other causality criteria were often used in place of CIOMS (eg, World Health Organization causality criteria and Karch-Lasagna), 10, 11, [15] [16] [17] [18] [19] which were not appropriate measures of causality for liverrelated case reports. [11] [12] [13] It should also be noted that no suspect ingredient or product has been common to all the published case reports involving Herbalife products to date and some reports even fail to identify the products involved. It is critical to properly characterize the agents in any suspected adverse event reports as a basis for determining the most likely mechanisms of action involved.
In conclusion, we feel that it is important for the journal and its readership to be aware of the different and more current perspectives regarding Herbalife case reports so that a more informed opinion can be reached in future assessments involving our products.
